nach oben

Current Urology Reports

Erschienen in:

01.10.2018 | New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Contrast-Enhanced Transrectal Ultrasound in Focal Therapy for Prostate Cancer

verfasst von: Akbar N. Ashrafi, Nima Nassiri, Inderbir S. Gill, Mittul Gulati, Daniel Park, Andre L. de Castro Abreu

Erschienen in: Current Urology Reports | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Contrast-enhanced transrectal ultrasound (CeTRUS) is an emerging imaging technique in prostate cancer (PCa) diagnosis and treatment. We review the utility and implications of CeTRUS in PCa focal therapy (FT).

Recent Findings

CeTRUS utilizes intravenous injection of ultrasound-enhancing agents followed by high-resolution ultrasound to evaluate tissue microvasculature and differentiate between benign tissue and PCa, with the latter demonstrating increased enhancement. The potential utility of CeTRUS in FT for PCa extends to pre-, intra- and post-operative settings. CeTRUS may detect PCa, facilitate targeted biopsy and aid surgical planning prior to FT. During FT, the treated area can be visualized as a well-demarcated non-enhancing zone and continuous real-time assessment allows immediate re-treatment if necessary. Following FT, the changes on CeTRUS are immediate and consistent, thus facilitating repeat imaging for comparison during follow-up. Areas suspicious for recurrence may be detected and target-biopsied. Enhancement can be quantified using time-intensity curves allowing objective assessment and comparison.

Summary

Based on encouraging early outcomes, CeTRUS may become an alternative imaging modality in prostate cancer FT. Further study with larger cohorts and longer follow-up are needed.

Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update. J Am Soc Echocardiogr. 2018;31(3):241–74.CrossRefPubMed

• Dietrich CF, Averkiou M, Nielsen MB, et al. How to perform contrast-enhanced ultrasound (CEUS). Ultrasound Int Open. 2018;4(1):E2–E15. This manuscript provides a great review of ultrasound enhancing agents, how to perform contrast-enhanced ultrasound, and the technical parameters to optimize CEUS performance. CrossRefPubMedPubMedCentral

Brannigan M, Burns PN, Wilson SR. Blood flow patterns in focal liver lesions at microbubble-enhanced US. Radiographics. 2004;24(4):921–35.CrossRefPubMed

Correas JM, Meuter AR, Singlas E, Kessler DR, Worah D, Quay SC. Human pharmacokinetics of a perfluorocarbon ultrasound contrast agent evaluated with gas chromatography. Ultrasound Med Biol. 2001;27(4):565–570.

Platts DG, Luis SA, Roper D, Burstow D, Call T, Forshaw A, et al. The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort. Heart Lung Circ. 2013;22(12):996–1002.CrossRefPubMed

Wei K, Main ML, Lang RM, Klein A, Angeli S, Panetta C, et al. The effect of Definity on systemic and pulmonary hemodynamics in patients. J Am Soc Echocardiogr. 2012;25(5):584–8.CrossRefPubMed

Parker JM, Weller MW, Feinstein LM, Adams RJ, Main ML, Grayburn PA, et al. Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts. Am J Cardiol. 2013;112(7):1039–45.CrossRefPubMed

Appis AW, Tracy MJ, Feinstein SB. Update on the safety and efficacy of commercial ultrasound contrast agents in cardiac applications. Echo Res Pract. 2015;2(2):R55–62.CrossRefPubMedPubMedCentral

Seitz K, Strobel D. A milestone: approval of CEUS for diagnostic liver imaging in adults and children in the USA. Ultraschall Med. 2016;37(3):229–32.CrossRefPubMed

10.

Halpern DF, Eliot L, Bigler RS, Fabes RA, Hanish LD, Hyde J, et al. Education. The pseudoscience of single-sex schooling. Science. 2011;333(6050):1706–7.CrossRefPubMed

11.

Bailey C, Huisman T, de Jong RM, Hwang M. Contrast-enhanced ultrasound and elastography imaging of the neonatal brain: a review. J Neuroimaging. 2017;27(5):437–41.CrossRefPubMed

12.

Miyamoto Y, Ito T, Takada E, Omoto K, Hirai T, Moriyasu F. Efficacy of sonazoid (perflubutane) for contrast-enhanced ultrasound in the differentiation of focal breast lesions: phase 3 multicenter clinical trial. Am J Roentgenol. 2014;202(4):W400–7.CrossRef

13.

Lekht I, Gulati M, Nayyar M, Katz MD, ter-Oganesyan R, Marx M, et al. Role of contrast-enhanced ultrasound (CEUS) in evaluation of thermal ablation zone. Abdom Radiol (NY). 2016;41(8):1511–21.CrossRef

14.

Gao M, Tang J, Liu K, Yang M, Liu H. Quantitative evaluation of vascular microcirculation using contrast-enhanced ultrasound imaging in rabbit models of choroidal melanoma. Invest Ophthalmol Vis Sci. 2018;59(3):1251–62.CrossRefPubMed

15.

Ran L, Zhao W, Zhao Y, Bu H. Value of contrast-enhanced ultrasound in differential diagnosis of solid lesions of pancreas (SLP): a systematic review and a meta-analysis. Medicine (Baltimore). 2017;96(28):e7463.CrossRef

16.

Wei X, Li Y, Zhang S, Xin XJ, Zhu L, Gao M. The role of contrast-enhanced ultrasound (CEUS) in the early assessment of microvascularization in patients with aggressive B-cell lymphoma treated by rituximab-CHOP: a preliminary study. Clin Hemorheol Microcirc. 2014;58(2):363–76.PubMed

17.

Guo S, Xu P, Zhou A, Wang G, Chen W, Mei J, et al. Contrast-enhanced ultrasound differentiation between low- and high- grade bladder urothelial carcinoma and correlation with tumor microvessel density. J Ultrasound Med. 2017;36(11):2287–97.CrossRefPubMed

18.

D'Onofrio M, Crosara S, De Robertis R, Canestrini S, Mucelli RP. Contrast-enhanced ultrasound of focal liver lesions. Am J Roentgenol. 2015;205(1):W56–66.CrossRef

19.

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.CrossRefPubMed

20.

O'Neal D, Cohen T, Peterson C, Barr RG. Contrast-enhanced ultrasound-guided radiofrequency ablation of renal tumors. J Kidney Cancer VHL. 2018;5(1):7–14.CrossRefPubMedPubMedCentral

21.

Du J, Li H-L, Zhai B, Chang S, Li F-H. Radiofrequency ablation for hepatocellular carcinoma: utility of conventional ultrasound and contrast-enhanced ultrasound in guiding and assessing early therapeutic response and short-term follow-up results. Ultrasound Med Biol. 2015;41(9):2400–11.CrossRefPubMed

22.

Zhou XD, Ren XL, Zhang J, He GB, Zheng MJ, Tian X, et al. Therapeutic response assessment of high intensity focused ultrasound therapy for uterine fibroid: utility of contrast-enhanced ultrasonography. Eur J Radiol. 2007;62(2):289–94.CrossRefPubMed

23.

Peng S, Hu L, Chen W, Chen J, Yang C, Wang X, et al. Intraprocedure contrast enhanced ultrasound: the value in assessing the effect of ultrasound-guided high intensity focused ultrasound ablation for uterine fibroids. Ultrasonics. 2015;58:123–8.CrossRefPubMed

24.

Zhang W, Li JM, He W, Pan XM, Jin ZQ, Liang T, et al. Ultrasound-guided percutaneous microwave ablation for benign breast lesions: evaluated by contrast-enhanced ultrasound combined with magnetic resonance imaging. J Thorac Dis. 2017;9(11):4767–73.CrossRefPubMedPubMedCentral

25.

Chen CN, Liang P, Yu J, Yu XL, Cheng ZG, Han ZY, et al. Contrast-enhanced ultrasound-guided percutaneous microwave ablation of renal cell carcinoma that is inconspicuous on conventional ultrasound. Int J Hyperth. 2016;32(6):607–13.CrossRef

26.

Li X, Liang P, Yu J, Yu XL, Liu FY, Cheng ZG, et al. Role of contrast-enhanced ultrasound in evaluating the efficiency of ultrasound guided percutaneous microwave ablation in patients with renal cell carcinoma. Radiol Oncol. 2013;47(4):398–404.CrossRefPubMedPubMedCentral

27.

Garbajs M, Popovic P. Contrast-enhanced ultrasound for assessment of therapeutic response after percutaneous radiofrequency ablation of small renal tumors. J BUON. 2016;21(3):685–90.PubMed

28.

Barwari K, Wijkstra H, van Delden OM, de la Rosette JJ, Laguna MP. Contrast-enhanced ultrasound for the evaluation of the cryolesion after laparoscopic renal cryoablation: an initial report. J Endourol. 2013;27(4):402–407.

29.

Sanz E, Hevia V, Arias F, et al. Contrast-enhanced ultrasound (CEUS): an excellent tool in the follow-up of small renal masses treated with cryoablation. Curr Urol Rep. 2015;16(1):469.

30.

van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM, et al. Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018. Eur Urol. 2018;74(1):84–91.CrossRefPubMed

31.

Coleman JA, Scardino PT. Targeted prostate cancer ablation: energy options. Curr Opin Urol. 2013;23(2):123–8.CrossRefPubMed

32.

Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 1995;55(15):3346–51.PubMed

33.

Beerlage HP, van Leenders GJ, Oosterhof GO, et al. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate. 1999;39(1):41–6.CrossRefPubMed

34.

Van Leenders GJ, Beerlage HP, Ruijter ET, de la Rosette JJ, van de Kaa CA. Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate. J Clin Pathol. 2000;53(5):391–4.CrossRefPubMedPubMedCentral

35.

Delon-Martin C, Vogt C, Chignier E, Guers C, Chapelon JY, Cathignol D. Venous thrombosis generation by means of high-intensity focused ultrasound. Ultrasound Med Biol. 1995;21(1):113–9.CrossRefPubMed

36.

Zlotta AR, Djavan B, Matos C, Noel JC, Peny MO, Silverman DE, et al. Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol. 1998;81(2):265–75.CrossRefPubMed

37.

Saksena M, Gervais D. Percutaneous renal tumor ablation. Abdom Imaging. 2008;34(5):582–7.CrossRefPubMed

38.

DeCastro GJ, Gupta M, Badani K, Hruby G, Landman J. Synchronous cryoablation of multiple renal lesions: short-term follow-up of patient outcomes. Urology. 2010;75(2):303–6.CrossRefPubMed

39.

Nakada SY, Lee FT Jr, Warner TF, Chosy SG, Moon TD. Laparoscopic renal cryotherapy in swine: comparison of puncture cryotherapy preceded by arterial embolization and contact cryotherapy. J Endourol. 1998;12(6):567–73.CrossRefPubMed

40.

Stephenson RA, King DK, Rohr LR. Renal cryoablation in a canine model. Urology. 1996;47(5):772–6.CrossRefPubMed

41.

Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33(2):223–31.CrossRefPubMed

42.

Huang H, Zhu ZQ, Zhou ZG, Chen LS, Zhao M, Zhang Y, et al. Contrast-enhanced transrectal ultrasound for prediction of prostate cancer aggressiveness: the role of normal peripheral zone time-intensity curves. Sci Rep. 2016;6:38643.CrossRefPubMedPubMedCentral

43.

Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H. Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int. 2012;110(11c):E794–808.CrossRefPubMed

44.

McClure P, Elnakib A, El-Ghar MA, et al. <I>in-vitro</I> and <I>in-vivo</I> diagnostic techniques for prostate Cancer: a review. J Biomed Nanotechnol. 2014;10(10):2747–77.CrossRefPubMed

45.

Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993;24(2):220–6.CrossRefPubMed

46.

Ismail M, Petersen RO, Alexander AA, Newschaffer C, Gomella LG. Color doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival. Urology. 1997;50(6):906–12.CrossRefPubMed

47.

Wildeboer RR, Postema AW, Demi L, Kuenen MPJ, Wijkstra H, Mischi M. Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer. Eur Radiol. 2017;27(8):3226–34.CrossRefPubMed

48.

Wink M, Frauscher F, Cosgrove D, Chapelon JY, Palwein L, Mitterberger M, et al. Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. Eur Urol. 2008;54(5):982–92.CrossRefPubMed

49.

Quaia E. Microbubble ultrasound contrast agents: an update. Eur Radiol. 2007;17(8):1995–2008.CrossRefPubMed

50.

Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013;39(2):187–210.CrossRefPubMed

51.

Sedelaar JPM, van Leenders GJLH, Hulsbergen-van de Kaa CA, et al. Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer. Eur Urol. 2001;40(3):285–93.CrossRefPubMed

52.

Seitz M, Gratzke C, Schlenker B, Buchner A, Karl A, Roosen A, et al. Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol. 2011;29(3):295–301.CrossRefPubMed

53.

Aigner F, Pallwein L, Mitterberger M, Pinggera GM, Mikuz G, Horninger W, et al. Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate. BJU Int. 2009;103(4):458–63.CrossRefPubMed

54.

Zhao H-X, Xia C-X, Yin H-X, Guo N, Zhu Q. The value and limitations of contrast-enhanced transrectal ultrasonography for the detection of prostate cancer. Eur J Radiol. 2013;82(11):e641–7.CrossRefPubMed

55.

Xie SW, Li HL, Du J, et al. Contrast-enhanced ultrasonography with contrast-tuned imaging technology for the detection of prostate cancer: comparison with conventional ultrasonography. BJU Int. 2012;109(11):1620–6.CrossRefPubMed

56.

Halpern EJ, Gomella LG, Forsberg F, McCue PA, Trabulsi EJ. Contrast enhanced transrectal ultrasound for the detection of prostate cancer: a randomized, double-blind trial of dutasteride pretreatment. J Urol. 2012;188(5):1739–45.CrossRefPubMedPubMedCentral

57.

• Rouviere O, Glas L, Girouin N, et al. Prostate cancer ablation with transrectal high-intensity focused ultrasound: assessment of tissue destruction with contrast-enhanced US. Radiology. 2011;259(2):583–91. This study showed that CeTRUS is able to demonstrate tissue ablation immediately and up to 1.5 months after whole gland HIFU therapy. CrossRefPubMed

58.

Sano F, Uemura H. The utility and limitations of contrast-enhanced ultrasound for the diagnosis and treatment of prostate cancer. Sensors. 2015;15(3):4947–57.CrossRefPubMedPubMedCentral

59.

Zhu Y, Chen Y, Jiang J, Wang R, Zhou Y, Zhang H. Contrast-enhanced harmonic ultrasonography for the assessment of prostate cancer aggressiveness: a preliminary study. Korean J Radiol. 2010;11(1):75–83.CrossRefPubMed

60.

• de Castro Abreu AL, Ashrafi AN, Gill IS, et al. Contrast-enhanced Transrectal Ultrasound (CeTRUS) for Follow-up After Focal Ablation of Prostate: Case Series. Journal of Ultrasound in Medicine. 2018. https://doi.org/10.1002/jum.14765. In this series, CeTRUS was used intra- and post-operatively with 12 months follow-up demonstrating good correlation with prostate biopsy and mpMRI. This was the first series evaluating CeTRUS following focal ablation with HIFU.

61.

Liu J-B, Merton DA, Wansaicheong G, Forsberg F, Edmonds PR, Deng XD, et al. Contrast enhanced ultrasound for radio frequency ablation of canine prostates: initial results. J Urol. 2006;176(4):1654–60.CrossRefPubMed

62.

Liu J-B, Wansaicheong G, Merton DA, Chiou SY, Sun Y, Li K, et al. Canine prostate: contrast-enhanced US-guided radiofrequency ablation with urethral and neurovascular cooling—initial experience. Radiology. 2008;247(3):717–25.CrossRefPubMed

63.

Cheng HL, Haider MA, Dill-Macky MJ, Sweet JM, Trachtenberg J, Gertner MR. MRI and contrast-enhanced ultrasound monitoring of prostate microwave focal thermal therapy: an in vivo canine study. J Magn Reson Imaging. 2008;28(1):136–43.CrossRefPubMed

64.

Shoji S, Uchida T, Nakamoto M, Kim H, de Castro Abreu AL, Leslie S, et al. Prostate swelling and shift during high intensity focused ultrasound: implication for targeted focal therapy. J Urol. 2013;190(4):1224–32.CrossRefPubMed

65.

Muller BG, van den Bos W, Brausi M, Fütterer JJ, Ghai S, Pinto PA, et al. Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World J Urol. 2015;33(10):1503–9.CrossRefPubMedPubMedCentral

66.

Rouviere O. Imaging techniques for local recurrence of prostate cancer: for whom, why and how? Diagn Interv Imaging. 2012;93(4):279–90.CrossRefPubMed

67.

Notley M, Yu J, Fulcher AS, Turner MA, Cockrell CH, Nguyen D. Diagnosis of recurrent prostate cancer and its mimics at multiparametric prostate MRI. Br J Radiol. 2015;88(1054):20150362.CrossRefPubMedPubMedCentral

68.

De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol. 2010;194(6):1427–33.CrossRefPubMed

69.

Kim CK, Park BK, Lee HM, Kim SS, Kim E. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. Am J Roentgenol. 2008;190(5):1180–6.CrossRef

70.

Sedelaar JP, Aarnink RG, van Leenders GJ, et al. The application of three-dimensional contrast-enhanced ultrasound to measure volume of affected tissue after HIFU treatment for localized prostate cancer. Eur Urol. 2000;37(5):559–68.CrossRefPubMed

71.

Sosnowski R, Zagrodzka M, Borkowski T. The limitations of multiparametric magnetic resonance imaging also must be borne in mind. Cent European J Urol. 2016;69(1):22–3.PubMedPubMedCentral

72.

Kirkham AP, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology. 2008;246(3):833–44.CrossRefPubMed

73.

Rouviere O, Lyonnet D, Raudrant A, et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol. 2001;40(3):265–74.CrossRefPubMed

74.

Rouviere O, Girouin N, Glas L, et al. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol. 2010;20(1):48–55.CrossRefPubMed

75.

Wondergem N, Rosette JJMCH DL. HIFU and cryoablation – non or minimal touch techniques for the treatment of prostate cancer. Is there a role for contrast enhanced ultrasound? Minim Invasive Ther Allied Technol. 2007;16(1):22–30.CrossRefPubMed

76.

Apfelbeck M, Clevert DA, Ricke J, Stief C, Schlenker B. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1. Clin Hemorheol Microcirc. 2018;69:93–100.CrossRefPubMed

77.

Pieters B, Wijkstra H, Herk MV, et al. Clinical Investigations Contrast-enhanced ultrasound as support for prostate brachytherapy treatment planning. J Contemp Brachytherapy. 2012;2:69–74.CrossRef

78.

• Beyer LP, Pregler B, Nießen C, Michalik K, Haimerl M, Stroszczynski C, et al. Percutaneous irreversible electroporation (IRE) of prostate cancer: contrast-enhanced ultrasound (CEUS) findings during follow up. Clin Hemorheol Microcirc. 2017;64(3):501–6. This retrospective study demonstrated the utility of CeTRUS in assessing efficacy of focal IRE therapy up to 6 months after treatment. CrossRef

79.

• van den Bos W, de Bruin DM, van Randen A, Engelbrecht MR, Postema AW, Muller BG, et al. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy. Eur Radiol. 2016;26(7):2252–60. This prospective study of 12 patients showed good correlation between CeTRUS and histopathology. CrossRefPubMed

80.

Niessen C, Jung EM, Beyer L, et al. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings. Clin Hemorheol Microcirc. 2015;61(2):135–41.CrossRefPubMed

Titel: Contrast-Enhanced Transrectal Ultrasound in Focal Therapy for Prostate Cancer
verfasst von: Akbar N. Ashrafi
Nima Nassiri
Inderbir S. Gill
Mittul Gulati
Daniel Park
Andre L. de Castro Abreu
Publikationsdatum: 01.10.2018
Verlag: Springer US
Erschienen in: Current Urology Reports / Ausgabe 10/2018
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-018-0836-6

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Enhanced Endoscopy in Bladder Cancer

Approaches to Eliminate Radiation Exposure in the Management of Pediatric Urolithiasis

Use and Effectiveness of Antimicrobial Intravesical Treatment for Prophylaxis and Treatment of Recurrent Urinary Tract Infections (UTIs): a Systematic Review

Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate